

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
18 August 2022 (18.08.2022)



(10) International Publication Number
WO 2022/171192 A1

(51) International Patent Classification:

C07K 16/18 (2006.01) C12N 15/63 (2006.01)
C07K 16/46 (2006.01) A61K 39/395 (2006.01)
C07K 19/00 (2006.01) A61P 35/00 (2006.01)
C12N 15/13 (2006.01) C12P 21/08 (2006.01)

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/CN2022/076000

(22) International Filing Date:

11 February 2022 (11.02.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2021/076626
11 February 2021 (11.02.2021) CN
PCT/CN2021/109057
28 July 2021 (28.07.2021) CN

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(71) Applicant: ADAGENE PTE. LTD. [SG/SG]; 16 Raffles Quay, #33-03 Hong Leong Building, 048581 (SG).

(72) Inventor; and

(71) Applicant (for MN only): DU, Fangyong [US/CN]; c/o Adagene INC., 4F, Building C14, 218 Xinghu St., Suzhou Industrial Park, Jiangsu, Suzhou 215123 (CN).

(72) Inventors: LUO, Peter Peizhi; c/o ADAGENE INC., 4F, Building C14, 218 Xinghu St., Suzhou Industrial Park, Jiangsu, Suzhou 215123 (CN). LI, Yan; c/o ADAGENE INC., 4F, Building C14, 218 Xinghu St., Suzhou Industrial Park, Jiangsu, Suzhou 215123 (CN). LIU, Guizhong; c/o ADAGENE INC., 4F, Building C14, 218 Xinghu St., Suzhou Industrial Park, Jiangsu, Suzhou 215123 (CN).

(74) Agent: WU, FENG & ZHANG; 3 FL, Building 2, Yard 3, FengXiuZhongLu Road, Haidian District, Beijing 100094 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,

(54) Title: ANTI-CD3 ANTIBODIES AND METHODS OF USE THEREOF

(57) Abstract: The present application provides antibodies comprising an antigen-binding fragment of an anti-CD3 antibody having tailor-made affinity to CD3 in low to medium range. In some embodiments, the antibody further comprises an antigen-binding fragment that specifically binds to a target antigen, such as HER2, CD20, TROP2, BCMA, or CD19. Also provided are anti-CD3 antibodies, masked anti-CD3 antibodies (including activatable anti-CD3 antibodies), anti-CD20 antibodies, and masked anti-HER2 antibodies (including activatable anti-HER2 antibodies). The antibodies described herein are useful for treatment of cancer.

WO 2022/171192 A1